Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142 is registered in ClinicalTrials.gov with Proteostasis Therapeutics, Inc. as lead sponsor.

NCT NCT02846142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02846142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers
Lead sponsor
Proteostasis Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2016
Completion date
March 31, 2017
Enrollment
94 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteer